Latest Conference Coverage

The PhD candidate at the Barts MS Center in London discussed the upcoming Chariot MS study as well as further research she would like to conduct in personalized cladribine dosing.

Alise Carlson, MD, a resident at Cleveland Clinic, provided insight on how raising awareness for genetic leukodystrophies may ultimately improve misdiagnosis rates.

An update on the phase 1b study of Pfizer’s investigational DMD treatment was presented at the MDA 2021 conference.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed a number of presentations from ISC 2021.

Researchers conducted a post-hoc analysis of Study 19 to determine hazard ratios of milestone occurrences in amyotrophic lateral sclerosis.

The duo from the National Institutes of Health discussed the advantages of the ultra-high resolution imaging technology in research.

Preliminary results from the IGNITE-DMD trial also showed a decreased in creatine kinase levels and improvements on NSAA and PODCI.

The postdoctoral researcher at Columbia University discussed the long-term plans to gain a better understanding of MS diagnosis disclosure and how it can impact other qualities of life.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed the abundance of research from the Florida Stroke Registry presented at ISC 2021.

The PhD candidate at the Barts MS Center in London discussed her study presented at ACTRIMS Forum 2021 that evaluated CPD in patients with relapsing MS.

Researchers observed improvements in motor and respiratory function and biomarkers in the investigational treatment group.

Alise Carlson, MD, a resident at Cleveland Clinic, detailed the reasons for her study evaluating genetic leukodystrophies and their differences to multiple sclerosis at diagnosis.

The triage software yielded a sensitivity and specificity of 59.7% and 91.5%, respectively, for all scans in a study including more than 1000.

Neurology News Network for the week ending March 27, 2021.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine outlined the Florida Stroke Registry and its capabilities.

The VBP-LTE study found no evidence of slowed linear growth, insulin resistance, or osteocalcin decreases.

P values showed evidence of statistical significance at the conventional P <.05 threshold for all assessed non-inferiority margins.

The senior investigator at the National Institutes of Neurological Disorders and Stroke outlined studies on anakinra and tolebrutinib as part of a new phase 2a clinical trial paradigm.

There was very good to excellent level of agreement between the instrumented insoles and the gold-standard reference system.

The Neuroimmunology Clinical Fellow at the National Institutes of Health discussed the evaluations of 2 therapies in multiple sclerosis that she is partaking in.

Two-year data from the SUNFISH study were presented at the MDA 2021 Clinical and Scientific Conference.

The postdoctoral researcher at Columbia University discussed ways clinicians and patients with multiple sclerosis can take to ease the transition of disclosing their diagnosis.

The AURORA collaboration studied pooled study data from 6 randomized studies of ET in ischemic stroke.

Researchers conducted a real-world study of prednisone to deflazacort switch in patients with Duchenne muscular dystrophy and Becker muscular dystrophy.

The neurologist from the University of Washington Medical Center discussed the findings of her recent study presented at ACTRIMS Forum 2021.

Black patients were 16% less likely and Asian patients were 30% less likely to be able to function independently compared to non-Hispanic white patients following endovascular treatment.

Assessment of forced vital capacity with treatment of enzyme replacement therapy generally showed some initial stability followed by slow progressive decline.

The findings were consistent with the established safety profile for eculizumab in other non-neurologic indications, according to study authors.